BioAffinity Technologies is developing technologies to detect cancers and diseases. There is an urgent need for non-invasive, early-stage cancer diagnosis and targeted cancer treatment. To address this, BioAffinity has created their first product, CyPath® Lung, that accurately diagnoses early-stage lung cancer, a leading cause of cancer-related deaths. CyPath® Lung is a flow cytometry test that reveals the lung microenvironment by characterizing cell populations in patients' sputum. BioAffinity has licensed CyPath® Lung to Precision Pathology Services for continued development and commercialization. Through their subsidiary, OncoSelect® Therapeutics, BioAffinity is also advancing therapeutic efforts by researching cancer-killing cytotoxic drugs. 

bioAffinity Technologies

Founded: 2014
Location: San Antonio, TX
Employee range: 11 - 50
Funding: $7.8M IPO Sep 2022; $4M A Aug 2017

Short description:

Drug notes:

Long description:

Jobs: